欧盟评估非转基因乳酸克鲁维酵母菌株AE

作者：张馨予

核心提示：2022年10月10日，欧盟食品安全局就一种β-半乳糖苷酶（β-galactosidase）的安全性评价发布意见。……（世界食品网-）

2022年10月10日，欧盟食品安全局就一种β-半乳糖苷酶（β-galactosidase）的安全性评价发布意见。
据了解，这种食品酶是由非转基因乳酸克鲁维酵母菌株AE-KL生产的，旨在用于牛奶加工（包括婴儿配方奶粉）、发酵乳制品生产和低聚半乳糖生产中的乳糖水解。

经过评估，专家小组认为，在预期的使用条件下，不能排除饮食暴露引起过敏反应的风险，但这种可能性被认为很低。根据所提供的数据，评估小组得出结论，这种食品酶在预期使用条件下不会引起安全问题。部分原文报道如下：

The food enzyme β-galactosidase (β-d-galactoside galatohydrolase, EC 3.2.1.23) is produced with the non-genetically modified Kluyveromyces lactis strain AE-KL by Amano Enzyme Inc. As the production strain meets the requirements for a Qualified Presumption of Safety (QPS) approach to safety assessment and as no other issues of concern were identified, the Panel considered that toxicological tests were not needed for the assessment of this food enzyme. The food enzyme is intended to be used for lactose hydrolysis in milk processing (including infant formulae), production of fermented milk products and manufacture of galacto-oligosaccharides (GOS). The dietary exposure to the food enzyme–total organic solids (TOS) was estimated to be up to 7.933 mg TOS/kg body weight (bw) per day in European populations. A search for similarity of the amino acid sequence of the food enzyme to known allergens was made and no match was found. The Panel considered that, under the intended conditions of use, the risk of allergic reactions by dietary exposure cannot be excluded, but the likelihood for this to occur is considered to be low. based on the QPS status of the production strain and the data provided, the Panel concluded that this food enzyme does not give rise to safety concerns, under the intended conditions of use.